Status:
COMPLETED
Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Overactive Bladder
Eligibility:
All Genders
Brief Summary
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Package Insert (unknown adverse drug reaction), 2) the incidence of adverse drug react...
Detailed Description
All the subjects whom an investigator prescribes the first Detrusitol Capsule should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolle...
Eligibility Criteria
Inclusion
- Male or female subjects intend to treat their overactive bladder who are prescribed Detrusitol Capsule by their physicians.
Exclusion
- Subjects who have been prescribed Detrusitol Capsule before.
Key Trial Info
Start Date :
December 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
11157 Patients enrolled
Trial Details
Trial ID
NCT01488578
Start Date
December 1 2006
End Date
March 1 2011
Last Update
January 28 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.